neugrin Inhibitors
Neugrin Inhibitors belong to a distinctive chemical class characterized by their specific interaction with neugrin, a neural growth-regulated protein. Neugrin is a key player in neuronal development and plasticity, influencing the intricate processes of neurite outgrowth and synaptic connectivity. Inhibitors within this class are designed to modulate the activity of neugrin, exerting a regulatory influence on neural circuits.
The chemical structure of neugrin inhibitors typically involves intricate arrangements of functional groups and molecular motifs that facilitate binding to neugrin receptors. Through precise molecular interactions, these inhibitors interfere with the signaling pathways associated with neugrin, thereby modulating neurodevelopmental processes. Researchers have focused on elucidating the precise mechanisms by which neugrin inhibitors exert their effects at the molecular level, aiming to unravel the intricate interplay between neugrin and its inhibitors. Understanding the structural nuances of neugrin inhibitors provides valuable insights into the potential manipulation of neuronal growth and connectivity, paving the way for further exploration of their biological implications.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Neugrin activity may be linked to cell cycle progression regulated by these kinases. Inhibition of CDK4/6 by palbociclib could disrupt the cell cycle, potentially leading to a decrease in neugrin activity due to altered cell cycle dynamics. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). Since neugrin may be involved in PI3K/Akt signaling, inhibition of this pathway by LY294002 could lead to reduced neugrin activity by preventing its phosphorylation and activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that may indirectly decrease neugrin activity. The mTOR pathway is crucial for protein synthesis and cell growth, and neugrin could be regulated by pathways downstream of mTOR. Inhibiting mTOR with rapamycin could reduce neugrin synthesis or impact its stability. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MAPK/ERK kinase (MEK). Neugrin could be a downstream effector in the MAPK/ERK pathway. By inhibiting MEK, U0126 may reduce ERK-mediated phosphorylation events that could be essential for neugrin's functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase. If neugrin is involved in the p38 MAPK pathway, inhibition of p38 with SB203580 could decrease neugrin's activity by interfering with stress response signaling that may regulate neugrin expression or activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, similar to LY294002, and could decrease neugrin activity by inhibiting the PI3K/Akt pathway. This would prevent the activation of downstream targets of Akt, potentially including neugrin, leading to its decreased activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK. By inhibiting MEK, PD98059 may prevent the activation of the MAPK/ERK pathway, which could be essential for neugrin's function. As a result, neugrin's activity could be diminished through the prevention of necessary phosphorylation events. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). Neugrin activity could be regulated via the JNK signaling pathway. Inhibition of JNK by SP600125 could lead to reduced neugrin activity if neugrin is modulated by JNK-mediated signaling events. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with a broad spectrum, including Src family kinases. If neugrin is activated or regulated by Src kinase signaling, dasatinib could decrease neugrin activity by inhibiting these kinases, thus preventing neugrin's phosphorylation and activation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. Neugrin could be degraded by the ubiquitin-proteasome system. Inhibition of the proteasome by bortezomib could lead to altered degradation of regulatory proteins that control neugrin activity, resulting in its decreased function. | ||||||